Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment

Journal of Medical Virology

Volumn 81, Issue 3, 2009, Pages 481-487

  Sarmati, L ^a   Andreoni, C ^b   Nicastri, E ^c   Tommasi, C ^a   Buonomini, A ^a   D'Ettorre, G ^b   Corpolongo, A ^c   Dori, L ^a   Montano, M ^a   Volpi, A ^a   Narciso, P ^c   Vullo, V ^b   Andreoni, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

CD4+ cell count; Cellular HIV DNA quantitation; HIV infection; Interruption of HAART

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; TREATMENT DURATION; BLOOD; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 60049097895     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21424     Document Type: Article

References (35)

1. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genné D, Nüesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, Staccato Study Group. 2006. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial. Lancet 368:459-465.
2. Andreoni M, Parisi SG, Sarmati L, Nicastri E, Ercoli L, Mancino G, Sotgiu G, Mannazzu M, Trevenzoli M, Tridente G, Concia E, Aceti A. 2000. Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies of HIV-RNA and >500 CD4 cells treated with highly active antiretroviral therapy. AIDS 14:23-29.
3. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA. 2005. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 40:594-600.
4. Carr A, Cooper DA. 2000. Adverse effects of antiretroviral therapy. Lancet 356:1423-1430.
5. Clavel F, Hance AJ. 2004. HIV drug resistance. N Engl J Med 350:1023-1035.
6. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholié S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X, Trivacan ANRS 1269 trial group. 2006. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): A randomised trial. Lancet 367:1981-1989.
7. d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M, The Antiretroviral Therapy Cohort Collaboration. 2005. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 165:416-423.
8. El-Sadr W, Neaton J, The SMART Study Investigators. 2006. Episodic CD4-guided use of ART is inferior to continuous therapy: Results of the SMART Study. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, Abstract Book abstract 106LB.
9. Fagard C, Bandelier CY, Ananworanich J, Le Braz M, Günthard H, Perneger T, García F, Hirschel B, Staccato/SSITT Study Group. 2005. Biphasic decline of CD4 cell count during scheduled treatment interruptions. AIDS 19:439-441.
10. 6 cells/l. AIDS 19:287-294.
11. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006. UNAIDS unified budget and workplan, 2006-2007. (Accessed November 2, 2006, at http://data.aids.org/publications/irc-pub06/JC1147-UBW-en.pdf).
12. Kuller L, SMART Study Group. 2008. Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. 15th conference on retroviruses and opportunistic infections, Abstract Book, Abstract 139.
13. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. 2004. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4s: A controlled, prospective trial. AIDS 18:439-446.
14. McDermott JL, Giri AA, Martini I, Bono M, Giacomini M, Campelli A, Tagliaferro L, Cara A, Varnier OE. 1999. Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. J Clin Microbiol 37:2361-2365.
15. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD, EuroSIDA Study Group. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352:1725-1730.
16. Murri R, Ammassari A, Trotta MP, De Luca A, Melzi S, Minardi C, Zaccarelli M, Rellecati P, Santopadre P, Soscia F, Scasso A, Tozzi V, Ciardi M, Orofino GC, Noto P, Monforte A, Antinori A, Wu AW, AdICoNa Study Group. 2004. Patient-reported and physician-estimated adherence to HAART: Social and clinic center-related factors are associated with discordance. J Gen Intern Med 19:1104-1110.
17. Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K. 2005. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 40:728-734.
18. Orenstein JM, Bhat N, Yoder C, Fox C, Polis MA, Metcalf JA, Kovacs JA, Falloon J, Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
19. Palella FT, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Asehman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigation. N Eng J Med 338:853-860.
20. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B. 2000. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study. Arch Intern Med 160:1123-1132.
21. Pedersen C, Katzenstein T, Nielsen C, Lundgren JD, Gerstoft J. 1997. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: Relation to CD4 cell count and clinical course of primary infection. J Acquir Immune Defic Syndr Hum Retrovirol 16:93-99.
22. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. 2003. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 34:379-386.
23. Riva E, Antonelli G, Scagnolari C, Pistello M, Capobianchi MR, Monforte A, Pezzotti P, Dianzani F, I.CO.N.A. Study Group. 2003. Human immunodeficiency virus (HIV) DNA load and level of immunosuppression in treatment-naive HIV-1-infected patients. J Infect Dis 187:1826-1828.
24. Sarmati L, Parisi SG, Nicastri E, d'Ettorre G, Palmisano L, Andreotti M, Andreoni C, Giuliano M, Gatti F, Boldrin C, Palù G, Vullo V, Vella S, Andreoni M. 2005. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy. J Clin Microbiol 12:6183-6185.
25. Sarmati L, Parisi SG, Nicastri E, d'Ettorre G, Andreoni C, Dori L, Gatti F, Montano M, Buonomini AR, Boldrin C, Palù G, Vullo V, Andreoni M. 2007. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens. J Med Virol 79:880-886.
26. Skiest DJ, Morrow P, Allen B, McKinsey J, Crosby C, Foster B, Hardy RD. 2004. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL. J Acquir Immune Defic Syndr 37:1351-1357.
27. 3. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February Abstract Book, abstract 101.
28. Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Watcharananan S, Sathapatayavongs B. 2007. Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting. AIDS Res Ther 4:26.
29. Tarwater P, Parish M, Gallant J. 2003. Prolonged treatment interruption after immunologic response to highly active therapy. Clin Infect Dis 37:1541-1548.
30. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. 2006. CD4+ Count-Guided Interruption of Antiretroviral Treatment. N Engl J Med 355:2283-2296.
31. Thiébaut R, Pellegrin I, Chêne G, Viallard JF, Fleury H, Moreau JF, Pellegrin JL, Blanco P. 2005. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400-10(6) cells/l. AIDS 19:53-61.
32. Tommasi C, Nicastri E, Corpolongo A, Ivanovic J, Notari S, Ascenzi P, Andreoni M, Narciso P. 2008. Stopping antiretroviral therapy: Role for therapeutic drug monitoring. AIDS 22:315-316.
33. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, Lourenço M, Rothschild C, Rouzioux C. 2004. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 18:45-49.
34. Walker RE, Masur H, Lane HC, Davey RT. 2000. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. AIDS 14:1709-1715.
35. Yerly S, Günthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, Perrin L, Swiss HIV Cohort Study. 2004. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18:1951-1953.